Head-To-Head Review: Cyclerion Therapeutics (NASDAQ:CYCN) & Immutep (NASDAQ:IMMP)
Head-To-Head Review: Cyclerion Therapeutics (NASDAQ:CYCN) & Immutep (NASDAQ:IMMP)
Cyclerion Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500. Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) and Immutep (NASDAQ:IMMP – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.
Cyclerion Therapeutics（纳斯达克股票代码：CYCN — Get Rating）和Immutep（纳斯达克股票代码：IMMP — Get Rating）都是小型医疗公司，但哪一项是更优的投资？我们将根据两家公司的股息、风险、估值、分析师建议、盈利能力、机构所有权和收益进行对比。
Valuation & Earnings
估值与收益
This table compares Cyclerion Therapeutics and Immutep's top-line revenue, earnings per share (EPS) and valuation.
该表比较了Cyclerion Therapeutics和Immutep的收入收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclerion Therapeutics | $479,000.00 | 62.02 | -$51.65 million | ($1.09) | -0.63 |
| Immutep | $4.90 million | 35.26 | -$23.37 million | N/A | N/A |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| Cyclerion Therap | 479,000.00 美元 | 62.02 | -5165 万美元 | (1.09 美元) | -0.63 |
| Immutep | 490 万美元 | 35.26 | -2,337 万美元 | 不适用 | 不适用 |
Immutep has higher revenue and earnings than Cyclerion Therapeutics.
Immutep 的收入和收益高于 Cyclerion Therapeutics。
Analyst Ratings
分析师评级
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclerion Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Immutep | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| Cyclerion Therap | 0 | 0 | 0 | 0 | 不适用 |
| Immutep | 0 | 0 | 0 | 0 | 不适用 |
Volatility and Risk
波动性和风险
Cyclerion Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.
Cyclerion Therapeutics的beta值为2.1，这表明其股价的波动性比标准普尔500指数高110％。相比之下，Immutep的beta值为2.33，这表明其股价的波动性比标准普尔500指数高133％。
Profitability
盈利能力
This table compares Cyclerion Therapeutics and Immutep's net margins, return on equity and return on assets.
该表比较了Cyclerion Therapeutics和Immutep的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Cyclerion Therapeutics | -2,551.69% | -149.84% | -114.70% |
| Immutep | N/A | N/A | N/A |
| 净利润 | 股本回报率 | 资产回报率 | |
| Cyclerion Therap | -2,551.69% | -149.84% | -114.70% |
| Immutep | 不适用 | 不适用 | 不适用 |
Institutional & Insider Ownership
机构所有权和内部所有权
58.5% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 6.1% of Immutep shares are held by institutional investors. 13.2% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cyclerion Therapeutics的58.5％股份由机构投资者持有。相比之下，6.1％的Immutep股份由机构投资者持有。13.2％的Cyclerion Therapeutics股票由公司内部人士持有。相比之下，3.1％的Immutep股份由公司内部人士持有。强大的机构所有权表明，大型基金经理、对冲基金和捐赠基金认为，从长远来看，股票的表现将超过市场。
Summary
摘要
Immutep beats Cyclerion Therapeutics on 6 of the 9 factors compared between the two stocks.
比较两只股票的9个因素中，Immutep在6个因素上击败了Cyclerion Therapeutics。
About Cyclerion Therapeutics
关于 Cyclerion Therape
(Get Rating)
（获取评分）
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Cyclerion Therapeutics, Inc. 是一家临床阶段的生物制药公司，通过使用可溶性鸟苷环化酶（sGC）药理学从事严重和孤儿疾病治疗的发现、开发和商业化。其产品线包括几种 sGC 刺激剂，这是一种小分子，可与 sGC 上的一氧化氮协同作用，促进环状单磷酸鸟苷 (cGMP) 的产生。该公司成立于2018年9月6日，总部位于马萨诸塞州剑桥。
About Immutep
关于 Immutep
(Get Rating)
（获取评分）
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Immutep Ltd. 是一家临床阶段的生物技术公司，从事与癌症和自身免疫性疾病相关的 LAG-3 相关免疫疗法产品的开发。其产品包括 eftilagimod alpha (IMP321)、IMP761、leramilimab (IMP701) 和 GSK'781 (IMP731)。该公司成立于1987年5月21日，总部位于澳大利亚悉尼。
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Cyclerion Therapeutics 的新闻和评 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Cyclerion Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。